Docoh
Loading...

ABT Abbott Laboratories

Filed: 20 Nov 20, 4:07pm
Common Shares, Without Par Value ABT 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

November 20, 2020

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois��1-2189 36-0698440
(State or other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification No.)

 

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading 

Symbol(s)

Name of Each Exchange

on Which Registered

Common Shares, Without Par ValueABT

New York Stock Exchange

Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

As previously reported, Abbott has Agreements Regarding Change in Control (“Agreements”) with its named executive officers, other than Miles D. White, Abbott’s Executive Chairman, who is not party to an Agreement.

 

The Agreements provide that if Abbott gives notification of extension before the Expiration Date (December 31, 2020), the Agreement’s term shall continue through the second anniversary of the Expiration Date.

 

On November 20, 2020, Abbott notified the named executive officers who are party to the Agreements that the term of the Agreements was extended through December 31, 2022.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 ABBOTT LABORATORIES
  
  
Date:   November 20, 2020By:/s/ Robert E. Funck, Jr.
  Robert E. Funck, Jr.
  Executive Vice President, Finance and Chief Financial Officer